Brief: Chemomab Presents Data From Study Showing Cm-101 Reduced Inflammatory, Fibrogenesis-Related Biomarkers In Patients With Severe Lung Injury Derived From Covid-19
09/11/2022 15:31
Nov 9 (Reuters) - Chemomab Therapeutics Ltd CMMB.O :
* CHEMOMAB PRESENTS CLINICAL DATA FROM
INVESTIGATOR-INITIATED
STUDY SHOWING CM-101 REDUCED INFLAMMATORY AND
FIBROGENESIS-RELATED BIOMARKERS IN PATIENTS WITH SEVERE LUNG
INJURY DERIVED FROM COVID-19
Source text for Eikon: ID:nPn8l3RnBa
Further company coverage: CMMB.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update